Interfering with interferons in inflammatory bowel disease
- PMID: 16849343
- PMCID: PMC1856258
- DOI: 10.1136/gut.2005.090134
Interfering with interferons in inflammatory bowel disease
Abstract
Early experience of fontolizumab, a humanised anti‐interferon γ antibody, in active Crohn's disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trials
Conflict of interest statement
Conflict of interest: None declared.
Comment on
-
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.Gut. 2006 Aug;55(8):1138-44. doi: 10.1136/gut.2005.079434. Epub 2006 Feb 21. Gut. 2006. PMID: 16492717 Free PMC article. Clinical Trial.
-
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.Gut. 2006 Aug;55(8):1131-7. doi: 10.1136/gut.2005.079392. Epub 2006 Feb 28. Gut. 2006. PMID: 16507585 Free PMC article. Clinical Trial.
Similar articles
-
Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma.Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1630-40. doi: 10.1152/ajpgi.00294.2006. Epub 2007 Mar 8. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17347451
-
Evidence for a regulatory "defect" for CD4 positive intestinal T cells in vitro in patients with IBD compared to normals.Adv Exp Med Biol. 1995;371B:1267-71. Adv Exp Med Biol. 1995. PMID: 7502797 No abstract available.
-
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?Gut. 2007 Sep;56(9):1181-3. doi: 10.1136/gut.2006.115980. Gut. 2007. PMID: 17698862 Free PMC article.
-
Management of inflammatory bowel disease: past, present and future.Expert Rev Clin Immunol. 2012 May;8(4):303-5. doi: 10.1586/eci.12.13. Expert Rev Clin Immunol. 2012. PMID: 22607175 Review. No abstract available.
-
[Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].Dtsch Med Wochenschr. 2001 Jun 1;126 Suppl 1:S52-8. doi: 10.1055/s-2001-14492. Dtsch Med Wochenschr. 2001. PMID: 11450615 Review. German. No abstract available.
Cited by
-
Targeted Application of Functional Foods as Immune Fitness Boosters in the Defense against Viral Infection.Nutrients. 2023 Jul 28;15(15):3371. doi: 10.3390/nu15153371. Nutrients. 2023. PMID: 37571308 Free PMC article. Review.
-
Tetraspanin Tspan8 restrains interferon signaling to stabilize intestinal epithelium by directing endocytosis of interferon receptor.Cell Mol Life Sci. 2023 May 19;80(6):154. doi: 10.1007/s00018-023-04803-x. Cell Mol Life Sci. 2023. PMID: 37204469 Free PMC article.
-
How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer.Biomolecules. 2024 May 29;14(6):633. doi: 10.3390/biom14060633. Biomolecules. 2024. PMID: 38927037 Free PMC article. Review.
-
Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases.Immunity. 2009 Oct 16;31(4):539-50. doi: 10.1016/j.immuni.2009.09.002. Immunity. 2009. PMID: 19833085 Free PMC article. Review.
-
Development of a Gut-On-A-Chip Model for High Throughput Disease Modeling and Drug Discovery.Int J Mol Sci. 2019 Nov 12;20(22):5661. doi: 10.3390/ijms20225661. Int J Mol Sci. 2019. PMID: 31726729 Free PMC article.
References
-
- Panitch H S, Folus J S, Johnson K P. Recombinant IFN‐β inhibits IFN‐gamma production in MS. Ann Neurol 198722137
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous